Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2465398 | 0.80 | HSD17B10 (0.40) | HSD17B10KMT2ASMN1; SMN2HRH3HPGD | |
| SCHEMBL2434333 | 0.78 | SMN1; SMN2 (0.37) | HSD17B10KMT2ASMN1; SMN2HRH3HPGD | |
| SCHEMBL72596 | 0.76 | HRH3 (0.37) | KMT2ASMN1; SMN2HRH3HPGDCTSL | |
| SCHEMBL5681663 | 0.76 | GAA (0.33) | HSD17B10KMT2AHPGD | |
| SCHEMBL71665 | 0.75 | ALDH1A1 (0.40) | KMT2ASMN1; SMN2HRH3CTSL | |
| SCHEMBL71003 | 0.72 | HSD17B10 (0.36) | HSD17B10KMT2ASMN1; SMN2HRH3HPGD | |
| SCHEMBL3825201 | 0.69 | HSD17B10 (0.45) | HSD17B10KMT2ASMN1; SMN2HRH3HPGD | |
| SCHEMBL2429386 | 0.68 | SMN1; SMN2 (0.39) | KMT2ASMN1; SMN2HRH3HPGDCTSL | |
| SCHEMBL2438306 | 0.68 | ALDH1A1 (0.40) | KMT2ASMN1; SMN2HRH3CTSL | |
| SCHEMBL2434806 | 0.68 | ALDH1A1 (0.46) | KMT2ASMN1; SMN2HRH3CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | HSD17B10 651/4885KMT2A 568/4885SMN1; SMN2 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.